top of page

Advancing Cancer Treatment Through Next-Generation Peptide.

A faster, more affordable, and scalable approach to immunotherapy.

Provider:

Precision Restoration of Immune Surveillance

A New Clinical Modality in Immuno-Oncology Conventional immunotherapeutic approaches—including checkpoint inhibition, cytokine agonism, and adoptive cell therapy—rely on non-specific or systemic activation of immune pathways, often at the cost of increased toxicity, complex logistics, and limited applicability across tumor types. These therapies also assume intact antigen processing and presentation within the tumor microenvironment (TME), which is frequently disrupted in advanced malignancies.

​

 

Manna Corp’s platform introduces a novel class of synthetic peptide agents that operate downstream of the antigen processing machinery, directly reconstituting MHC-I-mediated tumor visibility. This enables tumor-localized immune activation without global immune stimulation—a paradigm shift in how we engage T cell cytotoxicity.

Targeted, Tumor-Specific Antigen Replacement

Our platform utilizes high-affinity, MHC-compatible peptides capable of displacing weakly immunogenic or self-tolerant ligands from the peptide-binding groove of MHC class I molecules. This action occurs at the extracellular surface of tumor cells, bypassing the intracellular proteasome-TAP pathway, which is commonly downregulated in immune-resistant cancers (e.g., B2M loss, TAP mutations, ERAP1/2 alterations) [Garrido et al., 2010; Rock et al., 2016].

  • This exogenous peptide exchange mechanism directly restores the tumor’s immunogenicity to circulating CD8+ T lymphocytes.

  • Immune activation is thus targeted, localized, and antigen-specific, minimizing the risk of off-tumor autoimmunity or systemic inflammatory toxicity.

Integrated Biomarker Strategy for Pharmacodynamic Monitoring

To support real-time monitoring and therapeutic personalization, the platform integrates a multi-dimensional biomarker suite, including:

  • Soluble β2-Microglobulin (sβ2M): Reflects increased MHC-I complex turnover and successful peptide displacement at the tumor interface [Martins et al., 2021; Kawaguchi et al., 2017].

  • Peripheral Blood Mononuclear Cell (PBMC) Transcriptomics: Enables detection of immune activation signatures (e.g., IFNG, GZMB, CXCL9) using non-invasive blood sampling.

  • Cell-free RNA (cfRNA): Detectable tumor- and immune-derived transcripts in plasma may provide dynamic feedback on tumor antigenicity and treatment response.

This biomarker framework provides actionable clinical insights into treatment efficacy, T cell recruitment, and early indicators of response or resistance.

Designed for Operational Simplicity and Clinical Scalability

The platform was built to fit seamlessly within contemporary oncology workflows:

  • No patient-specific cell manufacturing: The peptide is fully synthetic and does not require leukapheresis or ex vivo expansion.

  • No cryogenic storage or chain-of-identity constraints: Peptides are shelf-stable and delivered through standard infusion protocols.

  • No specialized infrastructure required: Compatible with outpatient oncology clinics and academic medical centers alike.

This design enables rapid integration into existing clinical settings, including community oncology networks, without altering care infrastructure.​

“It is not a matter of reactivating the immune system—it is a matter of restoring what the tumor suppressed: visibility. This therapy gives the immune system a second chance to do what it was always meant to do.”

Patient:

A New Way to Help Your Immune System See and Fight Cancer

Many cancer treatments work by trying to stimulate the immune system. But if your immune system can’t see the cancer cells in the first place, even strong immune therapies may not help. That’s the problem Manna Corp is solving.

Why Cancer Sometimes Goes Undetected by the Immune System

Your immune system is constantly scanning your body for signs of infection or abnormal cells. It does this by checking the "ID tags" that all your cells display on their surface. These tags are made by something called the MHC class I system, which presents small protein fragments (called peptides) for immune cells to inspect.

​

Cancer cells often hide by displaying the wrong tags—or very weak ones—making it harder for immune cells to recognize them as threats. This is one reason why some people don’t respond to current immunotherapies, like checkpoint inhibitors or CAR-T therapies.

What Makes Manna Corp’s Therapy Different

Manna Corp’s therapy uses a synthetic peptide—a small, lab-designed protein—that can replace the weak or hidden tag on cancer cells with a stronger, clearer one. It attaches directly to the surface of tumor cells, restoring their visibility to the immune system.

​

This helps your body’s natural immune defense (especially CD8+ T cells) to recognize the cancer cell and target it for destruction.

What It Means for You, the Patient

  • Tumor-Agnostic: Works across multiple cancer types, not just one specific kind

  • Less Toxic: Does not rely on full-body immune activation, reducing risk of side effects

  • More Accessible: Peptide-based therapy is easier to manufacture and more cost-efficient than many current options

  • Targeted: Helps your immune system act precisely where it’s needed—at the tumor site

 

This means you may be able to get the benefits of immunotherapy without some of the challenges seen with other treatments—like long hospital stays, severe inflammation, or high costs.

“Your immune system already knows how to fight. We’re helping it remember what to look for.”

bottom of page